AstraZeneca Plc’s (NYSE: AZN) shares had their best month since last April -- when the company announced it was working on the Covid-19 vaccine -- despite temporary suspensions in Europe and confusion over its U.S. data. In the meantime, Germany will halt the use of AstraZeneca Plc’s Covid-19 vaccine for people younger than 60 starting Wednesday after a handful of new cases of severe blood clots emerged. AZN shares remain with no profits for 2021.